Charles River Laboratories International, Inc. (CRL) is a publicly traded Healthcare sector company. As of October 13, 2026, CRL trades at $299.54 with a market cap of $14.41B and a P/E ratio of -60.94. CRL moved -1.48% today. Year to date, CRL is +51.32%; over the trailing twelve months it is +80.72%. Its 52-week range spans $91.86 to $333.30. Analyst consensus is strong buy with an average price target of $316.57. Rallies surfaces CRL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for CRL, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $299.54 |
| Market Cap | $14.41B |
| P/E Ratio | -60.94 |
| EPS | $-4.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $333.30 |
| 52-Week Low | $91.86 |
| Volume | 134.03K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.00B |
| Net Income | $-236.30M |
| Gross Margin | 0.00% |
16 analysts cover CRL: 0 strong buy, 14 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $316.57.